Global Pharma Group - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 15,538 | 14,259 | 13,381 | 16,379 | 21,476 | 24,393 | 101,432 | 37,905 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 2,456 | -517 | -1,160 | -729 | 314 | 5,949 | 21,757 | 17,178 |
| Equity | 186,091 | 185,574 | 184,414 | 183,754 | 184,068 | 190,017 | 211,774 | 228,951 |
| Liabilities | 11,700 | 10,588 | 10,209 | 17,633 | 18,497 | 18,533 | 9,298 | 20,669 |
| Non-current assets | 111,373 | 94,520 | 84,367 | 74,213 | 74,060 | 115,836 | 149,951 | 214,575 |
| Current assets | 86,418 | 101,642 | 110,256 | 127,174 | 128,505 | 92,714 | 71,121 | 35,045 |
| Total assets | 197,791 | 196,162 | 194,623 | 201,387 | 202,565 | 208,550 | 221,072 | 249,620 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,254 | 1,711 | 2,426 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -15.0% | -8.2% | -6.2% | +22.4% | +31.1% | +13.6% | +315.8% | -62.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 1.2% | -0.3% | -0.6% | -0.4% | 0.2% | 2.9% | 9.8% | 6.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 1.3% | -0.3% | -0.6% | -0.4% | 0.2% | 3.1% | 10.3% | 7.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 15.8% | -3.6% | -8.7% | -4.5% | 1.5% | 24.4% | 21.4% | 45.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 15,538 | 14,259 | 13,381 | 16,379 | 21,476 | 20,908 | 101,432 | 37,905 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Global Pharma Group - Social security debts
The company had no debts to Sodra
Global Pharma Group - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-03-26 | 2025-06-10 | 0.28 |
| 2025-03-20 | 2025-03-25 | 0.14 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Global Pharma Group, UAB (code 302735496) is a Private Limited Liability Company operating in rental and operating of own or leased real estate. In 2025, the company generated revenue of €37.9K and net profit of €17.2K, resulting in a profit margin of 45.3%. Revenue declined by 62.6% year on year from €101.4K in 2024, but remained 55.4% above the 2023 level of €24.4K, showing a volatile but still improved two-year trajectory. Net profit increased from €5.9K in 2023 to €21.8K in 2024 and then stayed positive at €17.2K in 2025. The balance sheet strengthened further in 2025, with total assets of €249.6K, equity of €229.0K and liabilities of €20.7K. The equity ratio stood at 91.7% and debt-to-equity at 0.09, indicating low leverage. Return on equity was 7.5% and return on assets 6.9%. Asset turnover remained modest at 0.15x, and revenue per employee in 2025 was €37.9K.